The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...
The Food and Drug Administration on Tuesday told Eli Lilly and Novo Nordisk to remove warnings about the risk of suicidal ...
The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.
Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...
The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...